Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

A treatment for alopecia areata could move forward despite a setback in a midstage clinical trial.

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push a new generation of obesity treatments while making sweeping changes to ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

This is the third of four planned U.S. manufacturing sites the pharmaceutical giant has unveiled this year, set to bring 450 ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

“This is such a great opportunity for citizens of Indiana to have access to cutting-edge trials and for it to be a priority in our state to match people with certain challenges to opportunities for ...

The final, formatted version of the article will be published soon. Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle composed of apolipoprotein B-100 covalently linked to ...